Alx Oncology Holdings Stock Analysis

Alx Stock Analysis Notes

About 88.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.57. Some equities with similar Price to Book (P/B) outperform the market in the long run. Alx Oncology Holdings recorded a loss per share of 2.97. The entity had not issued any dividends in recent years. ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. The company was founded in 2015 and is headquartered in South San Francisco, California. Alx Oncology operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 52 people. For more info on Alx Oncology Holdings please contact Jason Lettmann at 650 466 7125 or go to https://www.alxoncology.com.

Alx Oncology Holdings Investment Alerts

Alx Oncology Holdings Upcoming and Recent Events

Alx Largest EPS Surprises

View All Earnings Estimates

Alx Stock Institutional Investors

Note, although Alx Oncology's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Alx Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 78.06 M.

Alx Profitablity

Management Efficiency

Alx Oncology Holdings has return on total asset (ROA) of (0.4925) % which means that it has lost $0.4925 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9894) %, meaning that it created substantial loss on money invested by shareholders. Alx Oncology's management efficiency ratios could be used to measure how well Alx Oncology manages its routine affairs as well as how well it operates its assets and liabilities. As of the 30th of November 2024, Return On Tangible Assets is likely to drop to -0.7. In addition to that, Return On Capital Employed is likely to drop to -0.87. At this time, Alx Oncology's Total Assets are very stable compared to the past year. As of the 30th of November 2024, Non Current Assets Total is likely to grow to about 56.6 M, while Net Tangible Assets are likely to drop about 205.5 M.

Technical Drivers

As of the 30th of November, Alx Oncology shows the Standard Deviation of 4.48, risk adjusted performance of (0.09), and Mean Deviation of 3.37. Alx Oncology Holdings technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

Alx Oncology Holdings Price Movement Analysis

Alx Oncology Holdings Insider Trading Activities

Alx Oncology Outstanding Bonds

Alx Oncology Predictive Daily Indicators

Alx Oncology Forecast Models

Alx Oncology's time-series forecasting models are one of many Alx Oncology's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alx Oncology's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Alx Oncology prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Alx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Alx Oncology. By using and applying Alx Stock analysis, traders can create a robust methodology for identifying Alx entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Alx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Alx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Alx Oncology Holdings stock analysis indicators help investors evaluate how Alx Oncology stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Alx Oncology shares will generate the highest return on investment. By understating and applying Alx Oncology stock analysis, traders can identify Alx Oncology position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alx Oncology Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in interest. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alx Oncology. If investors know Alx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alx Oncology listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Alx Oncology Holdings is measured differently than its book value, which is the value of Alx that is recorded on the company's balance sheet. Investors also form their own opinion of Alx Oncology's value that differs from its market value or its book value, called intrinsic value, which is Alx Oncology's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alx Oncology's market value can be influenced by many factors that don't directly affect Alx Oncology's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Alx Oncology's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alx Oncology is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alx Oncology's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.